Biotest GmbH KGaA (LTS:0N6Z) Notes Receivable: £0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Biotest GmbH KGaA Notes Receivable?

Biotest GmbH KGaA LTS:0N6Z Notes Receivable is £0.00 Mil as of . 20.

Biotest GmbH KGaA's Notes Receivable for the quarter that ended in . 20 was £0.00 Mil.

Biotest GmbH KGaA Notes Receivable Related Terms

Biotest GmbH KGaA Notes Receivable Historical Data

* Premium members only.

The historical data trend for Biotest GmbH KGaA's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest GmbH KGaA Notes Receivable Chart

Biotest GmbH KGaA Annual Data
Trend
Notes Receivable

Biotest GmbH KGaA Semi-Annual Data
Notes Receivable

Biotest GmbH KGaA Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of £0.00 Mil mean?
Biotest GmbH KGaA (LTS:0N6Z) has a Notes Receivable of £0.00 Mil as of . 20. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biotest GmbH KGaA and its competitors.
Is Biotest GmbH KGaA's Notes Receivable too high?
Biotest GmbH KGaA's current Notes Receivable is £0.00 Mil.
How does Biotest GmbH KGaA's Notes Receivable compare to ?
Biotest GmbH KGaA's Notes Receivable of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biotest GmbH KGaA and its competitors. Biotest GmbH KGaA's current Notes Receivable is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest GmbH KGaA stock overvalued right now?
Biotest GmbH KGaA (LTS:0N6Z) has a current Notes Receivable of £0.00 Mil. The current Notes Receivable is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Biotest GmbH KGaA (LTS:0N6Z), the current Notes Receivable is £0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest GmbH KGaA Business Description

Comparable Companies
Biotest GmbH & Co KGaA is a specialist in haematology, clinical immunology, and intensive care medicine. The group develops, manufactures, and markets plasma proteins and biotherapeutic drugs. The group's value chain extends from pre-clinical and clinical development to world-wide marketing and distribution. It manufactures immunoglobulins, clotting factors, and albumins, which are derived from human blood plasma. The group markets its products in Europe, the Middle East, China, Australia, Africa, and the USA.